

# Aurelio Cafaro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2239039/publications.pdf>

Version: 2024-02-01

90  
papers

4,135  
citations

109137

35  
h-index

118652

62  
g-index

90  
all docs

90  
docs citations

90  
times ranked

2939  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. <i>Nature</i> , 1994, 371, 674-680.	13.7	592
2	HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. <i>Nature Medicine</i> , 2002, 8, 225-232.	15.2	299
3	Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. <i>Nature Medicine</i> , 1999, 5, 643-650.	15.2	288
4	Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses. <i>Journal of Immunology</i> , 2002, 168, 197-206.	0.4	158
5	Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). <i>Vaccine</i> , 2001, 19, 2862-2877.	1.7	135
6	Contribution of Nonneutralizing Vaccine-Elicited Antibody Activities to Improved Protective Efficacy in Rhesus Macaques Immunized with Tat/Env Compared with Multigenic Vaccines. <i>Journal of Immunology</i> , 2009, 182, 3718-3727.	0.4	128
7	Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability In Vivo by Human Immunodeficiency Virus-1 Tat Protein and Basic Fibroblast Growth Factor. <i>Molecular Biology of the Cell</i> , 2001, 12, 2934-2946.	0.9	110
8	HIV-1 Tat Protein Modulates the Generation of Cytotoxic T Cell Epitopes by Modifying Proteasome Composition and Enzymatic Activity. <i>Journal of Immunology</i> , 2004, 173, 3838-3843.	0.4	101
9	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. <i>PLoS ONE</i> , 2010, 5, e13540.	1.1	94
10	A Replication-Competent Adenovirus-Human Immunodeficiency Virus (Ad-HIV) tat and Ad-HIV env Priming/Tat and Envelope Protein Boosting Regimen Elicits Enhanced Protective Efficacy against Simian/Human Immunodeficiency Virus SHIV 89.6P Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2007, 81, 3414-3427.	1.5	80
11	Sequence Conservation and Antibody Cross-Recognition of Clade B Human Immunodeficiency Virus (HIV) Type 1 Tat Protein in HIV-1 Infected Italians, Ugandans, and South Africans. <i>Journal of Infectious Diseases</i> , 2003, 188, 1171-1180.	1.9	75
12	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. <i>Vaccine</i> , 2004, 22, 3258-3269.	1.7	70
13	Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 1999, 73, 4029-4041.	1.5	70
14	HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection. <i>Journal of Immunology</i> , 2009, 182, 2888-2897.	0.4	65
15	Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. <i>European Journal of Immunology</i> , 2003, 33, 1548-1556.	1.6	64
16	Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. <i>Aids</i> , 2006, 20, 2245-2261.	1.0	61
17	Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in <i>Macaca fascicularis</i> NK cells. <i>European Journal of Immunology</i> , 2001, 31, 3546-3556.	1.6	60
18	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. <i>PLoS ONE</i> , 2012, 7, e48781.	1.1	56

#	ARTICLE	IF	CITATIONS
19	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. <i>Retrovirology</i> , 2015, 12, 33.	0.9	55
20	Challenges in HIV Vaccine Research for Treatment and Prevention. <i>Frontiers in Immunology</i> , 2014, 5, 417.	2.2	52
21	SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. <i>Journal of Medical Primatology</i> , 2003, 29, 193-208.	0.3	51
22	Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. <i>Vaccine</i> , 2006, 24, 2049-2056.	1.7	50
23	Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. <i>Biochemical Journal</i> , 2006, 396, 371-380.	1.7	50
24	Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2004, 78, 3333-3342.	1.5	49
25	The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. <i>Vaccine</i> , 2008, 26, 727-737.	1.7	49
26	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014, 11, 49.	0.9	48
27	HIV-1 Infection of Primary Human Neuroblasts. <i>Virology</i> , 1995, 210, 221-225.	1.1	43
28	Enhancement of Human Immunodeficiency Virus (HIV) Replication in Human Monocytes by Low Titres of Anti-HIV Antibodies in Vitro. <i>Scandinavian Journal of Immunology</i> , 1989, 30, 425-434.	1.3	42
29	Molecular and Functional Characterization of NKG2D, NKp80, and NKG2C Triggering NK Cell Receptors in Rhesus and Cynomolgus Macaques: Monitoring of NK Cell Function during Simian HIV Infection. <i>Journal of Immunology</i> , 2005, 174, 5695-5705.	0.4	41
30	Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV89.6P infection. <i>Vaccine</i> , 2008, 26, 3312-3321.	1.7	40
31	Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. <i>Journal of Medical Primatology</i> , 2001, 30, 207-214.	0.3	39
32	Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. <i>Vaccine</i> , 2004, 22, 2910-2924.	1.7	39
33	HIV-1 Tat affects the programming and functionality of human CD8+ T cells by modulating the expression of T-box transcription factors. <i>Aids</i> , 2014, 28, 1729-1738.	1.0	39
34	HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development. <i>International Reviews of Immunology</i> , 2009, 28, 285-334.	1.5	38
35	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. <i>DNA and Cell Biology</i> , 2002, 21, 599-610.	0.9	35
36	The HIV-1 Tat Protein Induces the Activation of CD8+ T Cells and Affects In Vivo the Magnitude and Kinetics of Antiviral Responses. <i>PLoS ONE</i> , 2013, 8, e77746.	1.1	35

#	ARTICLE	IF	CITATIONS
37	Transcription Pattern of Human Herpesvirus 8 Open Reading Frame K3 in Primary Effusion Lymphoma and Kaposi's Sarcoma. <i>Journal of Virology</i> , 2001, 75, 7161-7174.	1.5	34
38	Virus-induced cytokines regulate circulating lymphocyte levels during primary SIV infections. <i>International Immunology</i> , 1997, 9, 703-712.	1.8	33
39	HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. <i>Retrovirology</i> , 2016, 13, 34.	0.9	33
40	The HIV-1 Tat protein affects human CD4+ T-cell programming and activation, and favors the differentiation of naïve CD4+ T cells. <i>Aids</i> , 2018, 32, 575-581.	1.0	33
41	Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. <i>Current Opinion in Biotechnology</i> , 2004, 15, 543-556.	3.3	32
42	Problems and emerging approaches in HIV/AIDS vaccine development. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 23-48.	1.0	31
43	Impact of Viral Dose and Major Histocompatibility Complex Class IB Haplotype on Viral Outcome in Mauritian Cynomolgus Monkeys Vaccinated with Tat upon Challenge with Simian/Human Immunodeficiency Virus SHIV89.6P. <i>Journal of Virology</i> , 2010, 84, 8953-8958.	1.5	30
44	Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. <i>Vaccine</i> , 2003, 21, 3972-3981.	1.7	28
45	Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. <i>FASEB Journal</i> , 2003, 17, 1-20.	0.2	28
46	Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. <i>Vaccine</i> , 2003, 21, 1103-1111.	1.7	27
47	Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules. <i>Vaccine</i> , 2011, 29, 6823-6829.	1.7	26
48	Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. <i>Virology</i> , 2005, 342, 1-12.	1.1	24
49	Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner. <i>Aids</i> , 2014, 28, 2189-2200.	1.0	24
50	Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. <i>Frontiers in Immunology</i> , 2019, 10, 233.	2.2	23
51	NKp44 expression, phylogenesis and function in non-human primate NK cells. <i>International Immunology</i> , 2009, 21, 245-255.	1.8	22
52	HIV-1 Tat vaccines. <i>Virus Research</i> , 2001, 82, 91-101.	1.1	21
53	Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 $\Delta$ V2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile <i>Escherichia coli</i> enterotoxin. <i>Vaccine</i> , 2008, 26, 1214-1227.	1.7	20
54	A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. <i>Vaccine</i> , 2011, 29, 2918-2932.	1.7	20

#	ARTICLE	IF	CITATIONS
55	Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 13-29.	1.4	19
56	Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. <i>Archives of Virology</i> , 2008, 153, 463-472.	0.9	18
57	Containment of Infection in Tat Vaccinated Monkeys After Rechallenge with a Higher Dose of SHIV89.6P<sub>cy243</sub>. <i>Viral Immunology</i> , 2009, 22, 117-124.	0.6	18
58	Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort. <i>BMC Infectious Diseases</i> , 2016, 16, 344.	1.3	18
59	Characteristics of the CD8+ lymphocytosis during primary simian immunodeficiency virus infections. <i>Aids</i> , 1997, 11, 959-968.	1.0	17
60	Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant 17V2 Env. <i>Microbes and Infection</i> , 2005, 7, 1392-1399.	1.0	17
61	Enhanced follicular dendritic cell function in lymph nodes of simian immunodeficiency virus-infected macaques: Consequences for pathogenesis. <i>European Journal of Immunology</i> , 1997, 27, 3214-3222.	1.6	16
62	An Attenuated Herpes Simplex Virus Type 1 (HSV1) Encoding the HIV-1 Tat Protein Protects Mice from a Deadly Mucosal HSV1 Challenge. <i>PLoS ONE</i> , 2014, 9, e100844.	1.1	15
63	Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. <i>Vaccine</i> , 2016, 34, 2216-2224.	1.7	14
64	Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. <i>Vaccines</i> , 2019, 7, 99.	2.1	14
65	Innovative Approaches to Develop Prophylactic and Therapeutic Vaccines against HIV/AIDS. <i>Advances in Experimental Medicine and Biology</i> , 2009, 655, 189-242.	0.8	13
66	Viral DNA Burden and Decline in Percentage of CD4-Positive Cells in the Lymphoid Compartment of SIV-Infected Macaques. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1269-1277.	0.5	12
67	Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. <i>Virology</i> , 2004, 324, 531-539.	1.1	12
68	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. <i>Expert Review of Vaccines</i> , 2020, 19, 71-84.	2.0	12
69	HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. <i>International Journal of Molecular Sciences</i> , 2021, 22, 317.	1.8	12
70	Candidate HIV-1 gp14017V2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. <i>Vaccine</i> , 2007, 25, 6882-6890.	1.7	11
71	Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.. <i>EBioMedicine</i> , 2021, 66, 103306.	2.7	11
72	Phenotype of chronic lymphocytic leukemia (CLL) B-Cells. <i>Blut</i> , 1987, 54, 43-49.	1.2	10

#	ARTICLE	IF	CITATIONS
73	Effect of MHC Haplotype on Immune Response upon Experimental SHIVSF162P4cy Infection of Mauritian Cynomolgus Macaques. <i>PLoS ONE</i> , 2014, 9, e93235.	1.1	10
74	Immune response and protection by DNA vaccines expressing antigen 85B of <i>Mycobacterium tuberculosis</i> . <i>FEMS Microbiology Letters</i> , 2006, 262, 210-215.	0.7	9
75	Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. <i>Medical Science Monitor</i> , 2006, 12, BR330-40.	0.5	9
76	HIV-1 Tat protein vaccination in mice infected with <i>Mycobacterium tuberculosis</i> is safe, immunogenic and reduces bacterial lung pathology. <i>BMC Infectious Diseases</i> , 2016, 16, 442.	1.3	8
77	Influence of MHC class I and II haplotypes on the experimental infection of Mauritian cynomolgus macaques with SHIV <sub>SF162P4cy</sub> . <i>Tissue Antigens</i> , 2012, 80, 36-45.	1.0	7
78	Non-neutralizing antibodies and vaccine-induced protection. <i>Retrovirology</i> , 2006, 3, S26.	0.9	6
79	Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience. <i>Seminars in Immunopathology</i> , 2006, 28, 289-301.	4.0	6
80	New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. <i>Archives of Virology</i> , 2021, 166, 2955-2974.	0.9	6
81	Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1489-1493.	1.4	4
82	Old and New Concepts and Strategies in HIV Vaccinology: A Report from a Workshop held in Rome on 17 June 2016. <i>Journal of AIDS &amp; Clinical Research</i> , 2016, 7, .	0.5	4
83	“ART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies” Expert Review of Vaccines, 2017, 17, 1-12.	2.0	4
84	Biocompatible Anionic Polymeric Microspheres as Priming Delivery System for Effective HIV/AIDS Tat-Based Vaccines. <i>PLoS ONE</i> , 2014, 9, e111360.	1.1	4
85	The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation. <i>Vaccines</i> , 2020, 8, 274.	2.1	3
86	Induction of Antibodies and T Cell Responses by a Recombinant Influenza Virus Carrying an HIV-1 Tat <sup>51-59</sup> Protein in Mice. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	2
87	Relevance of Monoclonal Antibody Phenotyping and of Genetic Studies in the Classification of T-Cell Leukemia/Lymphoma. <i>Oncology Research and Treatment</i> , 1987, 10, 134-136.	0.8	1
88	T-helper phenotype chronic lymphocytic leukemia (Thp-CLL): Characterization of an Italian case with particular biological findings. <i>Blut</i> , 1987, 54, 289-298.	1.2	1
89	NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS*. <i>Clinical Research and Regulatory Affairs</i> , 2001, 18, 293-327.	2.1	1
90	HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine. <i>Expert Review of Vaccines</i> , 0, , 1-11.	2.0	1